Nicotine patch plus nicotine lozenges increased smoking cessation rate more than placebo

Prochazka, Allan V.
May 2010
ACP Journal Club;5/18/2010, Vol. 152 Issue 5, p1
Academic Journal
The article reports on a study related to the effective use of nicotine patch and nicotine tablets that help in raising smoking cessation rate. As stated, the research was based on clinical trials of thousands of patients who had an alveolar carbon monoxide and motivated to quit smoking. However, it presents solid evidence of nicotine patch and lozenges where these single agents are considered as useful supplements to help patients to quit smoking as compared to placebo.


Related Articles

  • WARENIKLINA -- CHAMPIX NOWY, DOUSTNY LEK W TERAPII UZALEÅ»NIENIA NIKOTYNOWEGO. Kostka-Trąbka, Elśbieta; Woroń, Jarosław; Trąbka-Janik, Elśbieta // Problemy Terapii Monitorowanej;sep2007, Vol. 18 Issue 3, p191 

    Varenicline (Champix) is orally administered α4β2 nicotinic Ach receptor partial agonist and is the first agent in this class to be approved for use in smoking cessation. Varenicline is simultanousy acting as a partial antagonist by blocking the binding and consequent reinforcing effects...

  • Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans. Sofuoglu, Mehmet; Herman, Aryeh I.; Mooney, Marc; Waters, Andrew J. // Psychopharmacology;Nov2009, Vol. 207 Issue 1, p153 

    Varenicline, a partial nicotinic acetylcholine receptor (nAChR) agonist, is approved for smoking cessation. A few preclinical studies examined the pharmacological effects of varenicline, alone or in combination with nicotine. How varenicline affects the pharmacological effects of pure nicotine...

  • Varenicline’s effects on acute smoking behavior and reward and their association with subsequent abstinence. Perkins, Kenneth A.; Mercincavage, Melissa; Fonte, Carolyn A.; Lerman, Caryn // Psychopharmacology;Jun2010, Vol. 210 Issue 1, p45 

    Varenicline may aid smoking cessation by attenuating smoking behavior and reward. We compared the effects of varenicline versus placebo on smoking behavior and reward, assessed both prospectively and retrospectively, and related these effects to subsequent success in a brief simulated quit...

  • Efficacy of the nicotine inhaler in smoking reduction: A double‐blind, randomized trial. Rennard, Stephen I.; Glover, Elbert D.; Leischow, Scott; Daughton, David M.; Glover, Penny N.; Muramoto, Myra; Franzon, Mikael; Danielsson, Tobias; Landfeldt, Björn; Westin, Åke // Nicotine & Tobacco Research;Aug2006, Vol. 8 Issue 4, p555 

    Many smokers are not ready to quit but are interested in changing their smoking behavior, particularly if such a change is associated with a reduction in health risk. The present study evaluated the efficacy of the nicotine inhaler in reducing smoking. Exploratory studies assessed whether...

  • Varenicline is useful for smoking cessation. Cadden, Paul // Thorax;Feb2007, Vol. 62 Issue 2, p161 

    The article offers information on the importance of varenicline for smoking cessation. Accordingly, varenicline is a new drug that is a partial nicotine receptor agonist and antagonist designed to aid smoking cessation by modulating central dopamine release. The patients were randomized to...

  • Severity of tobacco abstinence symptoms varies by time of day. Perkins, Kenneth A.; Briski, Jessica; Fonte, Carolyn; Scott, John; Lerman, Caryn // Nicotine & Tobacco Research;Jan2009, Vol. 11 Issue 1, p84 

    Introduction:: The time of day in which craving, withdrawal, and other tobacco abstinence symptoms are assessed may moderate the influences of abstinence or medication on those symptoms.

  • Assessment of the effectiveness of sustained release Bupropion and intensive physician advice in smoking cessation. Singh, Pranav; Kumar, Raj // Lung India;Jan-Mar2010, Vol. 27 Issue 1, p11 

    Background: Tobacco use is the cause of immense burden on our nation in terms of mortality and morbidity, being the single leading cause of preventable illnesses and death. Smoking cessation interventions in our country will be the most cost effective of all interventions considering that the...

  • Selegiline Transdermal System (STS) as an Aid for Smoking Cessation. Kahn, Roberta; Gorgon, Liza; Jones, Karen; McSherry, Frances; Glover, Elbert D.; Anthenelli, Robert M.; Jackson, Thomas; Williams, Jill; Murtaugh, Cristin; Montoya, Ivan; Yu, Elmer; Elkashef, Ahmed // Nicotine & Tobacco Research;Mar2012, Vol. 14 Issue 3, p377 

    Introduction: This study examined the efficacy and safety of selegiline transdermal system (STS) and brief repeated behavioral intervention (BRBI) for smoking cessation in heavy smokers. We hypothesized that the quit rate of subjects who received STS and BRBI would be significantly greater than...

  • Toward Personalized Therapy for Smoking Cessation: A Randomized Placebo-controlled Trial of Bupropion. Patterson, F.; Schnoll, R. A.; Wileyto, E. P.; Pinto, A.; Epstein, L. H.; Shields, P. G.; Hawk, L. W.; Tyndale, R. F.; Benowitz, N.; Lerman, C. // Clinical Pharmacology & Therapeutics;Sep2008, Vol. 84 Issue 3, p320 

    The article reports on the randomized placebo-controlled trial of bupropion as a personalized therapy for smoking cessation. This study examined a group of smokers that were tested for pretreatment nicotine metabolism rate (NMR) to know whether a pretreatment of NMR could stop them from smoking...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics